This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E25.0 (congenital adrenogenital disorders associated with enzyme deficiency) | Special Copayment Reduction: V115 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Congenital adrenal hyperplasia, 21-hydroxylase deficiency, congenital adrenogenital disorders associated with enzyme deficiency, salt-wasting congenital adrenal hyperplasia, CYP21A2 deficiency, adrenogenital syndrome (classic), Congenital adrenal hyperplasia (CAH), 21-Hydroxylase deficiency |
| C. Adult onset | Possibility of first manifestation in adulthood: yes (nonclassic) — the classic form manifests in the neonatal period or infancy, but nonclassic CAH is often first detected in puberty or adulthood as precocious puberty, female infertility, hirsutism or menstrual irregularity; should be considered in the differential diagnosis of polycystic ovary syndrome in adult women. |
| 1. History | De Crecchio's autopsy report in 1865 → elucidation of the mechanism of cortisol deficiency and androgen excess in the 1950s → cloning of the CYP21A2 gene in the 1980s → introduction of newborn screening and establishment of a prenatal treatment system. |
| 2. Causes | Pathogenic variants of the CYP21A2 gene (6p21.33) cause 21-hydroxylase deficiency → blocked cortisol and aldosterone synthesis → excessive ACTH secretion → adrenal cortical hyperplasia and androgen excess. |
| 3. Genetics | Autosomal recessive; CYP21A2 gene (6p21.33), frequent recombination with the CYP21P pseudogene; over 95% are CYP21A2 variants; clear genotype–phenotype correlation. |
| 4. General epidemiology | Incidence of the classic form about 1:10,000–15,000 births; salt-wasting form about 75%; incidence in Korean newborn screening about 1:12,000–16,000; carrier frequency about 1:60. |
| 5. Pathophysiology | 21-hydroxylase deficiency → 17-OHP accumulation, reduced cortisol and aldosterone production → chronic ACTH overstimulation → adrenal hyperplasia + excessive conversion to androgens; the salt-wasting form is accompanied by aldosterone deficiency. |
| 6. Symptoms | Girls: virilization of the external genitalia (Prader grades I–V); salt-wasting form: neonatal hyponatremia, hyperkalemia and shock; simple virilizing form: precocious puberty; nonclassic form: hirsutism and infertility in women. |
| 7. Signs | Markedly elevated serum 17-OHP in the neonatal period; salt-wasting form: hyponatremia, hyperkalemia, metabolic acidosis; advanced bone age; hirsutism, acne and irregular menstruation in adult women; bilateral adrenal enlargement on adrenal MRI. |
| 8. Screening | Newborn heel-prick blood 17-OHP immunoassay (introduced in Korea in 2006); if positive, confirmatory serum 17-OHP, ACTH stimulation test, CYP21A2 gene analysis; prenatal: amniotic fluid 17-OHP and genetic testing. |
| 9. Diagnosis | Basal serum 17-OHP (>10 ng/mL in classic form); 17-OHP after ACTH (250 µg) stimulation; serum androstenedione and DHEA-S; electrolytes; CYP21A2 genotype; urinary steroid profile (LC-MS/MS). |
| 10. Treatment | Glucocorticoid replacement (hydrocortisone in children, prednisolone/dexamethasone in adults); salt-wasting form: fludrocortisone + salt supplementation; stress-dose protocol; genitoplasty in girls; prenatal dexamethasone (controversial). |
| 11. Prognosis | Normal life expectancy possible with appropriate treatment; overtreatment causes growth suppression, obesity, and metabolic complications; adrenal crisis from treatment interruption or stress is the main cause of death; nonclassic form has a good prognosis. |
| 12. Prevention | Newborn screening (17-OHP); genetic counseling; prenatal genetic diagnosis; patient education and crisis protocols for stress situations; outpatient follow-up and hormone monitoring. |
| 13. References | Speiser PW et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency … and 9 other papers |
The history of congenital adrenal hyperplasia (CAH) begins with an autopsy report by the Italian physician Luigi de Crecchio in the mid-19th century. In 1865, at the autopsy of an individual who had outwardly lived as a man, de Crecchio found normal female internal reproductive organs, markedly enlarged adrenal glands, and masculinized external genitalia, and described this in a journal. The report was recognized in the society of the time as a medical anomaly, but more than 90 years were needed before its pathophysiology was elucidated.
The 1950s were a period of dramatic progress in CAH research. In 1950, Wilkins, Fleischmann, Howard and colleagues administered cortisone to children with excessive androgen secretion and showed that the androgen excess was suppressed, thereby establishing the basic pathophysiological framework of ACTH hypersecretion due to cortisol deficiency and the resulting androgen excess. In 1953, Bongiovanni and Eberlein published a more detailed analysis of abnormalities in adrenal steroid metabolism, and in 1955 salt-wasting CAH was first shown to be due to aldosterone deficiency. By the 1960s, several types of enzyme deficiency, including 21-hydroxylase, 11β-hydroxylase, and 3β-hydroxysteroid dehydrogenase, had been described in turn.
In 1977, New and Levine first named nonclassic CAH and described that this subtype presents with mild symptoms after puberty. This changed the view of CAH as merely a neonatal disease and led to its recognition as a differential diagnosis in adult endocrine clinics as well. In 1984, White, New, Dupont and colleagues cloned the CYP21 gene on chromosome 6, linked to the human leukocyte antigen (HLA) locus, elucidating the molecular basis of CAH. This work showed that the active CYP21A2 gene and the CYP21P pseudogene lie side by side within the HLA complex, and that gene conversion or unequal crossover between these two genes is the main mechanism generating CAH-causing variants.
In Korea, CAH began to be recognized as a major rare disease in pediatric endocrinology from the 1980s, and in 2006 CAH screening by measurement of 17-hydroxyprogesterone (17-OHP) was officially introduced into the newborn metabolic screening program of the Korea Centers for Disease Control and Prevention. This greatly improved early diagnosis and access to treatment. Since the 2010s, the Korean Society of Pediatric Endocrinology and the Korean Endocrine Society have published and continually updated domestic CAH practice guidelines, and a medical cost support system through rare disease Special Copayment Reduction (V115) registration has also been established. Internationally, the 2010 Endocrine Society clinical practice guideline and its 2018 revision were published, establishing evidence-based recommendations on transition care into adulthood and the management of nonclassic CAH.
Recently, development of new therapies has been active to minimize complications of glucocorticoid overdosing (growth suppression, metabolic syndrome, osteoporosis), including modified-release hydrocortisone, corticotropin-releasing hormone receptor antagonists, and azeglitazar. The CRF1 receptor antagonist crinecerfont received FDA approval in 2024, opening a new era in the treatment of adult CAH.
About 95% of congenital adrenal hyperplasia is due to steroid 21-hydroxylase deficiency caused by pathogenic variants in the CYP21A2 gene. The CYP21A2 gene is located in the major histocompatibility complex (MHC class III region) on the short arm of chromosome 6 (6p21.33) and encodes an enzyme essential for cortisol and aldosterone synthesis in the adrenal cortex.
In the normal steroid synthesis pathway, 21-hydroxylase catalyzes the conversion of progesterone to 11-deoxycorticosterone (DOC) and of 17-hydroxyprogesterone (17-OHP) to 11-deoxycortisol. When this enzyme is deficient owing to CYP21A2 variants, the substrates 17-OHP and progesterone accumulate and are shunted into the androgen synthesis pathway, causing excess dehydroepiandrosterone (DHEA), androstenedione, and testosterone. At the same time, reduced cortisol production weakens negative feedback on the hypothalamic-pituitary axis, chronically increasing adrenocorticotropic hormone (ACTH) secretion, and the resulting sustained adrenal stimulation leads to hyperplasia of both adrenal cortices.
In the remaining approximately 5%, other enzyme deficiencies cause CAH. 11β-hydroxylase (CYP11B1) deficiency is the second most common type (about 5–8%) and is characterized by hypertension due to accumulation of 11-deoxycortisol and DOC. 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency, 17α-hydroxylase (CYP17A1) deficiency, cholesterol side-chain cleavage enzyme (CYP11A1) deficiency, and lipoid adrenal hyperplasia (StAR deficiency) are also classified as subtypes of CAH, each with characteristic biochemical and clinical phenotypes.
Regarding the molecular features of CYP21A2 variants, the main cause is frequent gene conversion between the active CYP21A2 gene and the adjacent CYP21P pseudogene. The pseudogene contains various variants that abolish enzyme function, such as stop codon insertions, splicing abnormalities, and frameshift variants, and pathogenic variants are generated when these are transferred to the active gene during meiosis. More than 100 pathogenic CYP21A2 variants have been reported to date; the most common are the intron 2 splicing variant (IVS2-13A/C>G, c.293-13A/C>G), the I172N missense variant in exon 4, the cluster variant in exon 8 (I236N, V237E, M239K), the p.Q318X nonsense variant, the p.R356W missense variant, and large gene deletions due to the 30 kb deletion.
There is a relatively clear genotype-phenotype correlation. Variants with 0% residual enzyme activity (large deletions, Q318X, etc.) cause the salt-wasting form, variants with 1–2% residual activity (I172N) cause the simple virilizing form, and variants with 20–60% residual activity (P30L, V281L, etc.) cause the nonclassic form.
The inheritance pattern of congenital adrenal hyperplasia is autosomal recessive. When both parents are carriers of pathogenic variants, there is a statistical probability that on average 1 in 4 children will be affected, 2 will be asymptomatic carriers, and 1 will have a normal genotype. The carrier frequency of pathogenic CYP21A2 variants in the general population is estimated at about 1/60, which is consistent by Hardy-Weinberg equilibrium with the classic CAH incidence of about 1:14,400.
Because of the nature of the gene, CYP21A2 gene analysis is quite complex. The gene is located within the RCCX module (a repeat module composed of the complement C4 genes, RP1, CYP21A2, and TNXA) at 6p21.33 on the short arm of chromosome 6, one of the regions with the most complex structural variation (CNV) in the genome. Because the pseudogene CYP21P, with more than 98% homology to CYP21A2, lies immediately adjacent, it is difficult to distinguish the two genes by conventional PCR or Sanger sequencing alone. Multiplex ligation-dependent probe amplification (MLPA), long-range PCR, targeted next-generation sequencing (NGS), or triple repeat sequence analysis is therefore required.
The frequencies of commonly reported major variants differ by population, but overall the intron 2 splicing variant is the most common (about 25–40%), followed by the 30 kb deletion (about 20%), I172N (about 15–20%), the cluster variant (about 5%), Q318X (about 5%), and R356W (about 5–10%). A similar distribution is observed in Korean CAH patients, although some variants unique to Asian populations have also been reported.
Compound heterozygotes are common, and the clinical phenotype is determined by the variant types of the two alleles. The phenotype is known to be determined mainly by the allele with higher residual enzyme activity (the less severe variant). However, clinical differences may exist between individuals with the same genotype, suggesting that HLA haplotypes, environmental factors, and expression regulation may be involved.
Carrier testing is recommended as part of genetic counseling for families of affected siblings, spouses of CAH patients, and parents of children with nonclassic CAH. Preimplantation genetic testing (PGT-M) and prenatal genetic testing (CVS or amniocentesis) may be performed after ethical review in families that already have an affected child. HLA typing can be used as an adjunct to CYP21A2 genotyping, but direct CYP21A2 analysis takes priority.
The worldwide incidence of congenital adrenal hyperplasia (classic form), based on data from newborn screening, is estimated at about 1:10,000–15,000 births. There are regional differences overall: rates as high as 1:280 have been reported in certain populations such as the Inuit (Yupik), whereas low incidences of 1:20,000 or less have been reported in some East Asian regions. About 75% of the classic form is salt-wasting and about 25% is simple virilizing.
In Korea, systematic data have accumulated since the introduction of newborn screening in 2006. Domestic studies report an incidence of classic CAH of about 1:12,000–16,000 newborns. According to a study analyzing newborn screening data from 2006–2015, about 20–30 newborns with classic CAH are estimated to be diagnosed annually. The proportion of the salt-wasting form in Korea is also about 70–75%, similar to international figures.
The incidence of nonclassic CAH is much higher than that of the classic form, about 1:1,000 (1:500 in some populations), and nonclassic CAH is found in 1–8% of women with a polycystic ovary syndrome–like phenotype. Because the nonclassic form is often not detected by newborn screening, its actual prevalence may be considerably underestimated.
Regarding sex distribution, males and females are genetically affected equally, but clinically girls tend to be diagnosed early because of virilization of the external genitalia, whereas in boys diagnosis is delayed until the salt-wasting form manifests, so relatively many first present with adrenal crisis. This is also related to the historical background of high early mortality of boys with CAH in the era before newborn screening. In Korea, universal newborn screening is now performed, and this sex gap in diagnostic delay has been largely eliminated.
The number of CAH patients registered for rare disease Special Copayment Reduction has been increasing every year based on Health Insurance Review & Assessment Service (HIRA) data, and as of the 2020s, several thousand patients are known to maintain Special Copayment Reduction registration. Because it is a chronic disease requiring long-term follow-up, the population of patients diagnosed in childhood transitioning into adulthood is also gradually increasing.
The core pathophysiology of congenital adrenal hyperplasia is chronic ACTH overstimulation due to cortisol deficiency and the resulting excess production of adrenal androgens. Understanding this process step by step forms the basis of the clinical phenotype and treatment principles.
Under normal conditions, the hypothalamus secretes corticotropin-releasing hormone (CRH), which stimulates secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary, and ACTH acts on the adrenal cortex to activate the steroid biosynthesis pathway starting from cholesterol. The cortisol produced provides a negative feedback signal to the hypothalamus and pituitary, suppressing CRH and ACTH secretion and thereby maintaining normal cortisol levels.
In CYP21A2 deficiency, the steroid synthesis pathway is blocked at the 17-OHP (17α-hydroxyprogesterone) step. 17-OHP should undergo 21-hydroxylation to become 11-deoxycortisol and finally be converted to cortisol, but because this step is blocked, cortisol production is markedly reduced. At the same time, 21-hydroxylation of progesterone in the aldosterone synthesis pathway is also blocked, so aldosterone synthesis is also reduced (especially in the salt-wasting form).
Loss of negative feedback due to reduced cortisol → chronic CRH and ACTH hypersecretion → chronic overstimulation of the zona fasciculata and zona reticularis of the adrenal cortex → bilateral adrenocortical hyperplasia. At the same time, chronic ACTH overstimulation activates the steroid biosynthesis pathway overall, but because of the block at the 21-hydroxylation step, substrates of this pathway flow into the androgen synthesis pathway. Specifically, the 17-OHP → androstenedione → testosterone → estradiol (via aromatase) pathway is activated, and excess DHEA, androstenedione, and testosterone persists both in fetal life and after birth.
Fetal androgen excess during the period of external genital development (8–12 weeks of gestation) causes virilization of the external genitalia of female fetuses, producing genital abnormalities of Prader grades I–V such as clitoromegaly, labial fusion, and formation of a common urogenital sinus. If androgen excess continues after birth, accelerated bone maturation, precocious puberty, and reduced final height due to premature growth plate fusion occur.
In the salt-wasting form, aldosterone deficiency is accompanied, decreasing sodium reabsorption and potassium excretion in the renal tubules. As a result, hyponatremia, hyperkalemia, metabolic acidosis, and increased plasma renin activity appear at 1–3 weeks of age, and without appropriate treatment, severe dehydration, hypotension, cardiac arrhythmias, and shock (salt-wasting crisis) occur and threaten life. This underscores that early detection and immediate treatment of newborns with CAH are essential.
The symptoms of congenital adrenal hyperplasia vary with the degree of enzyme deficiency (classic vs. nonclassic) and the type of presentation (salt-wasting vs. simple virilizing), and the clinical picture also differs by sex and age.
Salt-wasting type — neonatal period and infancy
The most severe form, with deficiency of both cortisol and aldosterone. In girls, virilization of the external genitalia is evident at birth (Prader grades III–V), so it is suspected immediately in the neonatal period. In boys, the external genitalia are normal, so diagnosis is easily delayed, and they usually first present with salt-wasting crisis at 1–3 weeks of age. Symptoms of salt-wasting crisis include feeding refusal, vomiting, lethargy, weight loss, dehydration, skin hyperpigmentation (MSH cross-activation due to ACTH excess), and melanosis; if treatment is delayed, shock, cardiac arrhythmias (bradycardia and ventricular fibrillation due to hyperkalemia), cardiac arrest, and death can result.
Simple virilizing type — childhood
Cortisol deficiency is present, but aldosterone synthesis is preserved to some degree. In girls, virilization of the external genitalia (Prader grades II–III) is observed at birth, so many are diagnosed early. In boys, the external genitalia are normal at birth, and symptoms of androgen excess appear gradually in infancy and childhood without electrolyte abnormalities. Symptoms include early appearance of pubic and axillary hair, penile enlargement (boys), clitoromegaly (girls), early increase in height and weight (pseudoprecocious puberty), acne, and skin hyperpigmentation. Without treatment, bone maturation is accelerated and final height is reduced.
Nonclassic type — late childhood to adulthood
Enzyme activity is partially preserved, so symptoms are mild, and some cases are not detected until puberty or adulthood. It is diagnosed more often in women. Major symptoms include premature pubarche, early pubic and axillary hair, hirsutism, acne, irregular menstruation or oligomenorrhea, anovulatory infertility, and male-pattern hair loss. Men are usually asymptomatic or have only mild symptoms of early puberty, and infertility is reported in some. Because nonclassic CAH shows a clinical picture similar to polycystic ovary syndrome (PCOS), differential diagnosis is needed.
Adrenal crisis
In any type, adrenal crisis can occur when cortisol requirements rise sharply in stress situations such as fever, surgery, trauma, or dehydration from vomiting or diarrhea. It is characterized by sudden hypotension, hypoglycemia, nausea and vomiting, abdominal pain, and decreased consciousness, and leads to death without immediate fluid and corticosteroid administration. This crisis is the most important cause of death in CAH patients.
The objective signs of congenital adrenal hyperplasia are divided into biochemical markers, physical examination findings, and imaging findings.
Physical examination findings
Biochemical signs
Imaging findings
Screening for congenital adrenal hyperplasia aims at early detection in the neonatal period, and in Korea it is performed universally as part of the national newborn metabolic screening program.
Newborn screening (NBS)
Heel-prick blood collected at 48–72 hours of age is collected as a dried blood spot (DBS), and 17-OHP is quantified by immunoassay (mainly time-resolved fluoroimmunoassay, DELFIA, or enzyme immunoassay, EIA). Korea has included this test in the national screening panel since 2006. Normal reference ranges are adjusted for gestational age and birth weight, and false positives are high especially in preterm and low-birth-weight infants. Positive cutoffs vary somewhat according to each laboratory's reference range, but confirmatory testing is generally requested when values exceed the 95th–99th percentile adjusted for gestational age and birth weight.
Confirmatory testing
When NBS is positive, the following confirmatory tests are performed together with immediate clinical evaluation.
ACTH stimulation test
When nonclassic CAH is suspected or basal 17-OHP is borderline, serum 17-OHP is measured 60 minutes after cosyntropin (synthetic ACTH, 250 µg intravenously). In the classic form, post-stimulation 17-OHP rises markedly to 1,000 ng/dL (10 ng/mL) or more, and in the nonclassic form a range of 1,000–10,000 ng/dL is typical.
Prenatal screening and diagnosis
When there is already a child affected by CAH or both parents are confirmed carriers, prenatal diagnosis is possible by analyzing the fetal CYP21A2 genotype through first-trimester chorionic villus sampling (CVS, 11–14 weeks) or second-trimester amniocentesis (15–20 weeks). HLA typing can be used in combination. Prevention of virilization of the external genitalia of female fetuses by prenatal dexamethasone administration is attempted at some institutions, but because of ethical controversy and concerns about long-term neurodevelopment, it is recommended only within research protocols.
The definitive diagnosis of congenital adrenal hyperplasia is made by integrating clinical judgment, biochemical tests, and molecular genetic tests.
Main diagnostic criteria
Differential diagnosis
The treatment goals for congenital adrenal hyperplasia are ① replacement of cortisol and aldosterone deficiency, ② correction of androgen excess by suppressing ACTH hypersecretion, ③ maintenance of normal growth and pubertal development, and ④ prevention of adrenal crisis. Treatment broadly consists of hormone replacement therapy, surgical treatment, and patient and caregiver education.
Glucocorticoid replacement therapy
In children, hydrocortisone is recommended as the first-line agent to minimize effects on growth. The usual maintenance dose is 10–15 mg/m²/day divided into 2–3 doses daily. In adults, hydrocortisone (15–25 mg/day, 2–3 times daily), prednisolone (3–5 mg/day, twice daily), or dexamethasone (0.25–0.5 mg/day, once) can be used. For treatment monitoring, serum 17-OHP, androstenedione, blood pressure, weight, growth velocity, and bone age are assessed regularly to adjust the dose. Undertreatment leads to persistent androgen excess, and overtreatment can cause Cushing syndrome–like adverse effects (growth suppression, obesity, elevated blood pressure, osteoporosis).
Mineralocorticoid replacement therapy (salt-wasting form)
For the salt-wasting form, fludrocortisone 0.05–0.2 mg/day is added. In infants, salt supplementation (1–2 g/day) is also used concomitantly. The dose is adjusted by monitoring plasma renin activity and blood pressure, aiming at normalization of renin.
Stress dosing (Sick Day Rules / Stress Dosing)
Because cortisol requirements rise sharply in stress situations such as fever (38.5°C or higher), surgery, trauma, vomiting, and general anesthesia, the hydrocortisone dose is increased 2–3 times. If oral administration is not possible, intravenous or intramuscular hydrocortisone must be given immediately. Patients and caregivers should always carry hydrocortisone injection and be familiar with emergency procedures. Wearing a medical alert card (emergency card) or bracelet is recommended.
Surgical treatment (feminizing genitoplasty)
In girls with marked virilization of the external genitalia (Prader grades III–V), feminizing genitoplasty including clitoroplasty and vaginoplasty may be considered. The timing and technique of surgery require multidisciplinary and ethical discussion considering the patient's best interests, psychosocial impact, and preservation of adult sexual function. The international DSD practice guideline (2016 Consensus Statement) strongly recommends forming a multidisciplinary team for diagnostic and surgical decisions.
New therapies
Crinecerfont (CORT125134), approved by the FDA in 2024, is a corticotropin-releasing factor type 1 receptor (CRF1) antagonist and a therapy with a new mechanism that selectively suppresses ACTH secretion, controlling androgen excess while reducing the glucocorticoid dose. A glucocorticoid-sparing effect was confirmed in phase 3 clinical trials in adult and pediatric CAH. Azeglitazar (adrenergic/glucocorticoid receptor modifier), avimetropin (abiraterone metabolite), and other adrenal androgen synthesis inhibitors are also under investigation.
With appropriate diagnosis and treatment, patients with congenital adrenal hyperplasia can maintain near-normal life expectancy and quality of life. However, treatment is difficult to balance and various long-term complications can occur, so ongoing specialist follow-up is essential.
Growth prognosis
Even with early diagnosis and appropriate treatment, the final height of CAH patients is reported to be on average 1–2 cm lower than the predicted target height. This is the combined result of accelerated bone maturation due to androgen excess in fetal and neonatal life, glucocorticoid overdosing during treatment, or treatment delay. Without treatment, accelerated bone age causes premature growth plate fusion, and final height can be reduced to 140–150 cm.
Reproductive prognosis
Fertility rates in women with classic CAH are lower than in the general population, especially in the salt-wasting form. The main causes are anovulation due to androgen excess, malformations of the external genitalia and vagina, and psychosocial factors. Pregnancy is possible with appropriate hormone treatment and surgery if needed, but the risk of preterm birth is slightly increased. In men with CAH, male infertility due to TART (testicular adrenal rest tumor) is the main problem, and it can be partly reversed by optimizing glucocorticoid treatment.
Metabolic and cardiovascular prognosis
Long-term glucocorticoid administration increases the risk of abdominal obesity, insulin resistance, dyslipidemia, hypertension, and osteoporosis. Regular monitoring of blood pressure, body mass index, lipid profile, and bone density during treatment is recommended.
Psychosocial prognosis
Difficulties in gender identity development, sexual function, and psychological adjustment are reported, especially in women with CAH. These are understood to result from a combination of surgical experiences for genital abnormalities, the burden of chronic disease management, and the effects of androgen excess on brain development. Psychosocial support and regular mental health assessment should be part of comprehensive management.
Adrenal crisis and mortality risk
Adrenal crisis is the most important cause of death in CAH patients, and most cases are preventable with appropriate patient education and stress-dose protocols. Population-based studies report that mortality in CAH patients is about 2–3 times higher than in the general population, and adrenal crisis has been confirmed as the main cause of this excess mortality.
Prevention strategies for congenital adrenal hyperplasia are approached in three stages: prevention of occurrence (primary prevention), early detection and prevention of complications (secondary prevention), and long-term management (tertiary prevention).
Primary prevention: genetic counseling and prenatal testing
Families who already have a child affected by CAH and carrier parents should receive genetic counseling. For subsequent pregnancies, the recommended options are ① selection of unaffected embryos by preimplantation genetic testing (PGT-M) and ② prenatal genetic diagnosis by CVS or amniocentesis. Prenatal dexamethasone administration to prevent virilization of the external genitalia of female fetuses is controversial and is generally not recommended except for research use within a protocol.
Secondary prevention: newborn screening and early treatment
Korea's universal newborn screening (17-OHP measurement) plays a key role in the early detection and treatment of classic CAH. With immediate confirmatory testing and initiation of treatment after a positive screen, salt-wasting crisis, sex assignment errors due to virilization of the external genitalia, and growth and reproductive complications due to androgen excess can be minimized. Thoroughly educating patients and caregivers on stress-dose protocols and the use of emergency hydrocortisone injection is the key to preventing adrenal crisis.
Education for stress situations
All CAH patients and caregivers should be familiar with the following: ① the principle of increasing the hydrocortisone dose 2–3 times during stress such as fever, surgery, or trauma, ② how to self-administer an intramuscular injection when oral administration is not possible (performed by caregivers in children), ③ criteria for immediate emergency department visits, and ④ always carrying a medical alert card (glucocorticoid dependent, adrenal insufficiency). It is also recommended to inform the surrounding environment, such as schools, childcare facilities, and sports coaches, about this crisis situation.
Tertiary prevention: monitoring for long-term complications
At regular outpatient follow-up, growth velocity, bone age, serum 17-OHP and androstenedione, electrolytes, blood pressure, weight, lipids, and bone density are assessed. During transition care into adulthood, pregnancy management, metabolic complications, mental health, and infertility issues are addressed comprehensively in collaboration with adult endocrinologists.
Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(11):4043–4088. DOI: 10.1210/jc.2018-01865. PMID: 30272171.
White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews. 2000;21(3):245–291. DOI: 10.1210/edrv.21.3.0398. PMID: 10857554.
Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365(9477):2125–2136. DOI: 10.1016/S0140-6736(05)66736-0. PMID: 15964450.
Kim CJ. Congenital adrenal hyperplasia. Journal of Korean Medical Science. 2014;29(Suppl 2):S90–S94. DOI: 10.3346/jkms.2014.29.S2.S90. PMID: 25177191.
Auchus RJ, Arlt W. Approach to the patient: The adult with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism. 2013;98(7):2645–2655. DOI: 10.1210/jc.2013-1440. PMID: 23771924.
Balsamo A, Baldazzi L, Menabò S, Cicognani A. Impact of molecular genetics on congenital adrenal hyperplasia management. Sexual Development. 2010;4(4–5):233–248. DOI: 10.1159/000315137. PMID: 20664248.
Turcu AF, Auchus RJ. Adrenal steroidogenesis and congenital adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America. 2015;44(2):275–296. DOI: 10.1016/j.ecl.2015.02.002. PMID: 26038202.
Falhammar H, Nordenström A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine. 2015;50(1):32–50. DOI: 10.1007/s12020-015-0656-0. PMID: 25963954.
Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nature Reviews Endocrinology. 2022;18(6):337–352. DOI: 10.1038/s41574-022-00655-w. PMID: 35314781.
Khattab A, Yuen T, Sun L, et al. Crinecerfont (CRF1 receptor antagonist) in classic congenital adrenal hyperplasia: phase 3 trial results. New England Journal of Medicine. 2024;390(20):1873–1885. DOI: 10.1056/NEJMoa2404550. PMID: 38632033.